BioRestorative Therapies, Inc. (BRTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.38 |
| Open | 0.36 |
| Day High | 0.38 |
| Day Low | 0.35 |
| 52-Week High | 1.89 |
| 52-Week Low | 0.16 |
| Volume | 745,335 |
| Average Volume | 11.01M |
| Market Cap | 3.17M |
| PE | -0.33 |
| EPS | -1.06 |
| Moving Average 50 Days | 0.27 |
| Moving Average 200 Days | 0.88 |
| Change | -0.02 |
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026
GlobeNewswire Inc.
Mar 05, 2026 1:00 PM GMT
Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategy MELVILLE, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Compa
BioRestorative Therapies, Inc. Issues Letter to Shareholders Highlighting Major Milestones, Regulatory Alignment, Clinical Execution and Capital Strategy
GlobeNewswire Inc.
Mar 04, 2026 1:00 PM GMT
Company is well positioned following positive FDA Type B meeting outcome, fully enrolled Phase 2 trial for its lead clinical program, and recent $5 million public offering, as commercial operation continues to build momentum MELVILLE, N.Y., March 04
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs
GlobeNewswire Inc.
Feb 24, 2026 1:30 PM GMT
GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-l